ProCE Banner Activity

Call to Action: The Importance of ASCVD Risk Assessment and Achieving Targets Through Personalized LDL-C–Lowering Treatment Plans

Clinical Thought

In this commentary, read about the importance of achieving LDL-C targets and overcoming barriers to statin or nonstatin therapies to reduce ASCVD risk. To learn more, register for our live in-person or virtual symposium titled “Staying on Target: Reducing CV Risk by Achieving LDL-C Targets With Statin and Nonstatin Therapies” at the ACP 2024 Internal Medicine Meeting. 

Released: April 05, 2024

Expiration: April 04, 2025

Share

Faculty

Ty J. Gluckman

Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC

Medical Director
Center for Cardiovascular Analytics, Research, and Data Science (CARDS)
Providence Heart Institute
Providence Health System
Portland, Oregon

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation

Disclosure

Primary Author

Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC

Medical Director
Center for Cardiovascular Analytics, Research, and Data Science (CARDS)
Providence Heart Institute
Providence Health System
Portland, Oregon

Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC, has no relevant financial relationships to disclose.